DR. ALAIN L. FYMAT, PhD, PhD is a medical-physical scientist and an educator. He is the current President/CEO and Professor at the International Institute of Medicine & Science with a previous appointment as EVP/COO and Professor at the Weil Institute of Critical Care Medicine, California, U.S.A. He was formerly Professor of Radiology, Radiological Sciences, Radiation Oncology, Critical Care Medicine and Physics at several U.S. and European Universities. Earlier, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs (Office of Research Oversight). At the Loma Linda Veterans Affairs Medical Center, he was Scientific Director of Radiology, Director of the Magnetic Resonance Imaging Center and, for a time, Acting Chair of Radiology. Previously, he was also Director of the Division of Biomedical and Biobehavioral Research at the University of California at Los Angeles/Drew University of Medicine and Science. He is also Health Advisor to the American Heart & Stroke Association, Coachella Valley Division, California. He is a frequent Keynote Speaker and International Organizing Committee member at several international scientific conferences. He has lectured extensively in the U.S., Europe, Asia and Africa. He has published ~ 425 scholarly scientific publications and books. He is also Editor-in-Chief, Honorable Editor or Editor of 54 scientific Journals. Dr. Fymat is a Board member of several institutions, a member of the New York Academy of Sciences and a reviewer for the prestigious UNESCO Newton Prize, United Kingdom National Commission for UNESCO. His current research interests are focused on neurodegenerative diseases (Alzheimer, Parkinson, epilepsy, dementias and others), oncology, molecular/precision/personalized medicine, and nanomedicine and nanobiotechnology
Fymat’s current research interests lie at the interface between science and medicine, particularly cancer/oncology, molecular/personal/precision medicine, nanomedicine, human genetics/ epigenetics/ ecogenetics, neurodegenerative diseases, and pharmacogenomics. His most recent publications deal with nanotechnology and cancer, nano chemotherapy, nano neurology, natural and synthetic immunotherapy, drug delivery across the brain protective barriers, and neurodegenerative disorders.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
